Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Atopic dermatitis ups mortality risk in adults

23 Feb 2018

Atopic dermatitis (AD) in adults is associated with an increased risk of death, a recent study has found. Furthermore, AD patients have a slightly elevated risk of death from cardiovascular, urogenital and infectious diseases, but the absolute risk is very low.

A total of 8,686 patients were matched with 86,860 controls in this study that investigated cause-specific death rates and risk in adults with AD.

Patients with AD had significantly elevated risk for death due to any cause (hazard ratio [HR], 1.27; 95 percent CI, 1.11–1.45). Significant causes included the following: cardiovascular (HR, 1.45; 1.07–1.96), infectious (HR, 3.71; 1.43–9.60) and urogenital diseases (HR, 5.51; 1.54–19.80).

In addition, there was no increased mortality risk due to cancer, endocrine, neurologic, psychiatric, respiratory or gastroenterologic disease.

The investigators performed cross-linkage of nationwide healthcare and cause of death registers. Adults with AD were matched 1:10 with controls. Cox proportional hazard models were used to calculate incidence rates per 1,000 person-years and HRs of cause-specific death.

“The results might not be generalizable to patients seen exclusively by primary care physicians,” according to the investigators.

Apart from mortality risk, AD may have significant impact on adults. A recent article has suggested that visible lesions “necessarily have consequences on all aspects of everyday life, including sleep, and professional, social, family and emotional life,” as well as financial consequences. Furthermore, AD can greatly affect quality of life and be a heavy burden to these adult patients. [Ann Dermatol Venereol 2017;144(suppl 5):VS23-VS28]

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.